KR102403847B1 - 치료학적 단백질의 정제 방법 - Google Patents

치료학적 단백질의 정제 방법 Download PDF

Info

Publication number
KR102403847B1
KR102403847B1 KR1020217010484A KR20217010484A KR102403847B1 KR 102403847 B1 KR102403847 B1 KR 102403847B1 KR 1020217010484 A KR1020217010484 A KR 1020217010484A KR 20217010484 A KR20217010484 A KR 20217010484A KR 102403847 B1 KR102403847 B1 KR 102403847B1
Authority
KR
South Korea
Prior art keywords
fibrinogen
solution
resin
vwf
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217010484A
Other languages
English (en)
Korean (ko)
Other versions
KR20210042422A (ko
Inventor
헝 팜
제프리 미카엘 헤이
다렌 응웨이
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20210042422A publication Critical patent/KR20210042422A/ko
Application granted granted Critical
Publication of KR102403847B1 publication Critical patent/KR102403847B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020217010484A 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법 Active KR102403847B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261733761P 2012-12-05 2012-12-05
US61/733,761 2012-12-05
EP13153898 2013-02-04
EP13153898.5 2013-02-04
US13/803,740 2013-03-14
US13/803,740 US20140154233A1 (en) 2012-12-05 2013-03-14 Method of purifying therapeutic proteins
AU2013203357A AU2013203357B2 (en) 2012-12-05 2013-04-10 A method of purifying therapeutic proteins
AU2013203357 2013-04-10
PCT/AU2013/001414 WO2014085861A1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins
KR1020157017824A KR102240978B1 (ko) 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017824A Division KR102240978B1 (ko) 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법

Publications (2)

Publication Number Publication Date
KR20210042422A KR20210042422A (ko) 2021-04-19
KR102403847B1 true KR102403847B1 (ko) 2022-05-31

Family

ID=47630209

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217010484A Active KR102403847B1 (ko) 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법
KR1020157017824A Active KR102240978B1 (ko) 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157017824A Active KR102240978B1 (ko) 2012-12-05 2013-12-05 치료학적 단백질의 정제 방법

Country Status (12)

Country Link
US (5) US20140154233A1 (enExample)
EP (2) EP3483173A1 (enExample)
JP (3) JP6411360B2 (enExample)
KR (2) KR102403847B1 (enExample)
CN (2) CN109125714B (enExample)
AU (2) AU2013203357B2 (enExample)
BR (1) BR112015012854B1 (enExample)
CA (2) CA3185085A1 (enExample)
PL (1) PL2928905T3 (enExample)
RU (1) RU2685956C2 (enExample)
SG (2) SG11201504372UA (enExample)
WO (1) WO2014085861A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013135684A1 (en) 2012-03-13 2013-09-19 Octapharma Ag Improved process for production of fibrinogen and fibrinogen produced thereby
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2017118910A1 (en) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
WO2018007767A1 (fr) 2016-07-06 2018-01-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Fibrinogène liquide stable
IL265102B2 (en) * 2016-09-01 2023-11-01 Plas Free Ltd Human Blood-Derived Products Having Decreased Fibrinolytic Activity And Uses Thereof In Hemostatic Disorders
KR20200038309A (ko) * 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CA3215331A1 (en) 2021-04-13 2022-10-20 Toshiharu Motokubota Liquid composition comprising factor viii or factor viii/von willebrand factor complex
CN115181178B (zh) * 2021-09-04 2024-04-26 广东双林生物制药有限公司 一种从冷沉淀中制备人纤维蛋白原的方法
MX2024008243A (es) 2021-12-30 2024-09-04 Baxter Int Soluciones de fibrinogeno y trombina para un sellador de fibrina y un kit de sellador de fibrina.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083153A2 (en) 2010-01-08 2011-07-14 Profibrix Bv Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
KR101195777B1 (ko) * 2004-02-24 2012-11-05 체에스엘 베링 게엠베하 피브리노겐 정제 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
CA2117058A1 (en) * 1991-09-05 1993-03-18 Daphne C. Tse Topical fibrinogen complex
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
CA2195127C (en) * 1994-07-14 2007-06-19 Ruth Laub Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation
AU3463495A (en) * 1994-09-02 1996-03-27 New York Blood Center, Inc., The Production and secretion of recombinant fibrinogen by yeast
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
DE69931645T2 (de) * 1998-09-24 2007-05-16 Pharming Intellectual Property Bv Reinigung von fibrinogen aus flüssigkeiten mittels ausfällung und hydrophobischer-interaktion-chromatographie
DE60042343D1 (de) * 1999-12-23 2009-07-16 Csl Ltd Abtrennung von fibrinogen von plasmaproteasen
WO2001046016A1 (en) 1999-12-23 2001-06-28 Rast Rodger H System and method for providing individualized dosing
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
PL205685B1 (pl) * 2001-05-21 2010-05-31 Omrix Biopharm Sa Sposób in vitro usuwania lub wyodrębniania plazminogenu lub plazminy w obecności fibrynogenu, stałe podłoże powinowactwa do oczyszczania mieszaniny zawierającej fibrynogen i plazminę i/lub plazminogen oraz krioprecypitat
AUPR638801A0 (en) 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
JP2005508925A (ja) * 2001-10-03 2005-04-07 クリストファー ジェイ ウールヴァートン 貯蔵安定なフィブリノーゲン溶液
AU2002340776A1 (en) * 2001-10-30 2003-05-12 Novozymes A/S High throughput isolation of proteins by charge induction chromatography
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JP4319979B2 (ja) * 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
CA2583081A1 (en) * 2004-06-16 2006-01-19 Bio-Rad Laboratories, Inc. Multichemistry fractionation
ATE546520T1 (de) * 2007-01-04 2012-03-15 Crucell Holland Bv Faktor-xi-reinigung
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
WO2009090056A2 (en) 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
SI2300497T1 (sl) * 2008-06-24 2013-02-28 Octapharma Ag Postopek za äťiĺˇäťenje koagulacijskega faktorja viii
ES2586698T3 (es) * 2010-09-20 2016-10-18 Octapharma Ag Proceso para la producción de fibrinógeno
EP2649087A1 (en) * 2010-12-08 2013-10-16 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
WO2013135684A1 (en) 2012-03-13 2013-09-19 Octapharma Ag Improved process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101195777B1 (ko) * 2004-02-24 2012-11-05 체에스엘 베링 게엠베하 피브리노겐 정제 방법
WO2011083153A2 (en) 2010-01-08 2011-07-14 Profibrix Bv Fibrinogen preparations enriched in fibrinogen with an extended alpha chain

Also Published As

Publication number Publication date
CA3185085A1 (en) 2014-06-12
US11426680B2 (en) 2022-08-30
CA2893373A1 (en) 2014-06-12
BR112015012854A2 (pt) 2017-07-11
HK1214833A1 (en) 2016-08-05
EP3483173A1 (en) 2019-05-15
KR20150090252A (ko) 2015-08-05
CN104981476A (zh) 2015-10-14
JP2016501878A (ja) 2016-01-21
EP2928905A4 (en) 2016-06-08
PL2928905T3 (pl) 2019-05-31
US20190209948A1 (en) 2019-07-11
JP2021073280A (ja) 2021-05-13
JP6411360B2 (ja) 2018-10-24
RU2015126551A (ru) 2017-01-10
US20140154233A1 (en) 2014-06-05
AU2013354899A1 (en) 2015-07-16
JP2019011346A (ja) 2019-01-24
JP6836562B2 (ja) 2021-03-03
US20170143805A1 (en) 2017-05-25
JP7774384B2 (ja) 2025-11-21
BR112015012854B1 (pt) 2021-11-30
WO2014085861A1 (en) 2014-06-12
KR20210042422A (ko) 2021-04-19
CN104981476B (zh) 2018-10-09
SG10201704484QA (en) 2017-07-28
AU2013203357B2 (en) 2015-08-27
US20210283530A1 (en) 2021-09-16
CN109125714A (zh) 2019-01-04
US9598461B2 (en) 2017-03-21
KR102240978B1 (ko) 2021-04-19
EP2928905B1 (en) 2018-11-21
RU2685956C2 (ru) 2019-04-23
US20150158906A1 (en) 2015-06-11
SG11201504372UA (en) 2015-07-30
AU2013354899B2 (en) 2018-05-17
CN109125714B (zh) 2022-08-02
EP2928905A1 (en) 2015-10-14
AU2013203357A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
JP7774384B2 (ja) 治療タンパク質の精製方法
AU2003244850B2 (en) Processes for the preparation of fibrinogen
US10806755B2 (en) Plasma-supplemented formulation
US10188965B2 (en) Hydrophobic charge induction chromatographic depletion of a protein from a solution
HK40007788A (en) Separation of fibrinogen, fviii and/or vwf from plasma proteases by hcic
HK1214833B (en) A method of purifying therapeutic proteins
ES2711455T3 (es) Un método de purificación de proteínas terapéuticas
RU2559576C1 (ru) Способ получения вирусбезопасного полного протромбинового комплекса

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210408

Application number text: 1020157017824

Filing date: 20150702

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210506

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210514

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220225

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220527

End annual number: 3

Start annual number: 1

PG1601 Publication of registration